These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 29432966)

  • 1. Rapid oral desensitization protocol to abiraterone acetate.
    Verdu M; Torres-Degayon V; Hassan-Bennis M
    Ann Allergy Asthma Immunol; 2018 Jun; 120(6):668-669. PubMed ID: 29432966
    [No Abstract]   [Full Text] [Related]  

  • 2. [Update on the risk of corticosterone therapy in combination with abiraterone acetate during the COVID-19 pandemic].
    Rozet F; Mongiat-Artus P; Ploussard G; Rouprêt M; Cacoub P; Fournier G; Mathieu R
    Prog Urol; 2021 Apr; 31(5):243-244. PubMed ID: 33468416
    [No Abstract]   [Full Text] [Related]  

  • 3. Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.
    Saad F; Shore N; Van Poppel H; Rathkopf DE; Smith MR; de Bono JS; Logothetis CJ; de Souza P; Fizazi K; Mulders PF; Mainwaring P; Hainsworth JD; Beer TM; North S; Fradet Y; Griffin TA; De Porre P; Londhe A; Kheoh T; Small EJ; Scher HI; Molina A; Ryan CJ
    Eur Urol; 2015 Oct; 68(4):570-7. PubMed ID: 25985882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Not Available].
    Wolff JM
    Oncol Res Treat; 2017; 40 Suppl 2():11-12. PubMed ID: 28365709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Not Available].
    Miller K
    Oncol Res Treat; 2017; 40 Suppl 2():6-7. PubMed ID: 28365705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abiraterone Acetate for Nonmetastatic Castration-Resistant Prostate Cancer-The Forgotten Dance Partner?
    Klaassen Z; Wallis CJD; Fleshner NE
    JAMA Oncol; 2019 Feb; 5(2):144-145. PubMed ID: 30489621
    [No Abstract]   [Full Text] [Related]  

  • 7. Evaluation of prostate-specific antigen response following cessation of abiraterone acetate: is there evidence for a withdrawal syndrome?
    Azad AA; Eigl BJ
    Eur Urol; 2014 Feb; 65(2):504-5. PubMed ID: 24210911
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of Castration-naive Metastatic Prostate Cancer.
    Hamilou Z; Baciarello G; Fizazi K
    Eur Urol Focus; 2017 Dec; 3(6):518-521. PubMed ID: 29500136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequencing of Cabazitaxel and Abiraterone Acetate After Docetaxel in Metastatic Castration-Resistant Prostate Cancer: Treatment Patterns and Clinical Outcomes in Multicenter Community-Based US Oncology Practices.
    Sonpavde G; Bhor M; Hennessy D; Bhowmik D; Shen L; Nicacio L; Rembert D; Yap M; Schnadig I
    Clin Genitourin Cancer; 2015 Aug; 13(4):309-318. PubMed ID: 25743206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is it possible that one patient may again experience a response to abiraterone acetate withdrawal during an abiraterone acetate rechallenge?
    Maines F; Veccia A; Caffo O
    Eur Urol; 2014 Jul; 66(1):179-80. PubMed ID: 24685435
    [No Abstract]   [Full Text] [Related]  

  • 11. Osteoclast inhibitors in advanced prostate cancer: does the benefit extend beyond skeletal-related events?
    Geynisman DM; Ross EA; Plimack ER
    Eur Urol; 2015 Oct; 68(4):578-80. PubMed ID: 26116295
    [No Abstract]   [Full Text] [Related]  

  • 12. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.
    Ryan CJ; Smith MR; Fizazi K; Saad F; Mulders PF; Sternberg CN; Miller K; Logothetis CJ; Shore ND; Small EJ; Carles J; Flaig TW; Taplin ME; Higano CS; de Souza P; de Bono JS; Griffin TW; De Porre P; Yu MK; Park YC; Li J; Kheoh T; Naini V; Molina A; Rathkopf DE;
    Lancet Oncol; 2015 Feb; 16(2):152-60. PubMed ID: 25601341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rechallenge of docetaxel combined with epirubicin given on a weekly schedule in advanced castration-resistant prostate cancer patients previously exposed to docetaxel and abiraterone acetate: a single-institution experience.
    Petrioli R; Roviello G; Fiaschi AI; Laera L; Miano ST; De Rubertis G; Barbanti G; Bianco V; Brozzetti S; Francini E
    Med Oncol; 2015 Mar; 32(3):52. PubMed ID: 25636506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abiraterone acetate as a possible cause of sudden cardiac death.
    Sahin S; Karatas F; Eren T; Altinbas M; Altundag K
    J BUON; 2016; 21(3):751-2. PubMed ID: 27569102
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy, Tolerance, and Plasma Levels of Abiraterone and Its Main Metabolites in a Patient With Metastatic Castration-resistant Prostate Cancer With a Hepatic Transplant.
    van Nuland M; Janssen JM; van Hoek B; Rosing H; Beijnen JH; Bergman AM
    Clin Genitourin Cancer; 2019 Oct; 17(5):e893-e896. PubMed ID: 31248829
    [No Abstract]   [Full Text] [Related]  

  • 16. Cardiovascular safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients: a prospective evaluation.
    Prati V; Ruatta F; Aversa C; Gernone A; Galizia D; Bonzano A; Torino S; Nuzzolese I; Marandino L; Aglietta M; Ortega C
    Future Oncol; 2018 Feb; 14(5):443-448. PubMed ID: 29318908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate-Specific Antigen Flare Phenomenon During
    De Vincentis G; Follacchio GA; Frantellizzi V; Liberatore M; Monteleone F; Cortesi E
    Clin Genitourin Cancer; 2016 Oct; 14(5):e529-e533. PubMed ID: 27212044
    [No Abstract]   [Full Text] [Related]  

  • 18. Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies.
    Bellmunt J; Kheoh T; Yu MK; Smith MR; Small EJ; Mulders PF; Fizazi K; Rathkopf DE; Saad F; Scher HI; Taplin ME; Davis ID; Schrijvers D; Protheroe A; Molina A; De Porre P; Griffin TW; de Bono JS; Ryan CJ; Oudard S
    Eur Urol; 2016 May; 69(5):924-32. PubMed ID: 26508309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer.
    Tagawa ST; Posadas EM; Bruce J; Lim EA; Petrylak DP; Peng W; Kheoh T; Maul S; Smit JW; Gonzalez MD; De Porre P; Tran N; Nanus DM
    Eur Urol; 2016 Nov; 70(5):718-721. PubMed ID: 26852075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Corticosteroids in the management of advanced prostate cancer].
    Kübler H
    Urologe A; 2017 Feb; 56(2):217-223. PubMed ID: 27878318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.